NASDAQ · HRTX
Heron Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for HRTX: Nov 09, 2026
Heron Therapeutics, Inc. Common Stock is expected to report earnings on 11/09/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.03. The reported EPS for the same quarter last year was $-0.05.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Dec 2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · The Motley Fool · MarketBeat- RTTNews · Oct 20, 3:28 AM EDTCytoDyn Appoints Robert E. Hoffman As CEO; Lalezari To Focus On Research(RTTNews) – CytoDyn Inc. (CYDY), a clinical-stage biotechnology company developing leronlimab for oncology indications, announced the appointment of Robert E. Hoffman as Chief Executive Officer (CEO), effective October 20, 2026.
- BNK Invest · Oct 14, 3:21 PM EDTNotable Wednesday Option Activity: HRTX, GLNG, KNSLAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Heron Therapeutics Inc (Symbol: HRTX), where a total of 41,920 contracts have traded so far, representing approximately 4.2 million underlying shares. That amounts to ab
- The Motley Fool · Aug 17, 11:59 AM EDTHeron (HRTX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 12, 7:09 AM EDTHeron Incurs Wider Loss In Q2; Withdraws 2026 Guidance Amid Patent Litigation Over CINVANTI(RTTNews) – Heron Therapeutics Inc. (HRTX), a commercial-stage biotechnology company, on Monday released second quarter financial results noting a higher loss due to increased sales expenses and decreased sales of oncology drugs.
- MarketBeat · Aug 10, 10:04 AM EDTHeron Therapeutics Q2 Earnings Call HighlightsHeron Therapeutics (NASDAQ:HRTX) reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while management said sales of its key products came in below its internal expectations. Chief
- Zacks · Aug 10, 9:10 AM EDTHeron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue EstimatesHeron Therapeutics (HRTX) delivered earnings and revenue surprises of -50.00% and -11.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 7:10 PM EDTVerrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue EstimatesVerrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 9:00 AM EDTBioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue EstimatesBioCryst (BCRX) delivered earnings and revenue surprises of +114.29% and +18.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 15, 6:24 AM EDTNew Strong Sell Stocks for July 15thBV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
- The Motley Fool · May 11, 3:34 PM EDTHeron (HRTX) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 11, 11:07 AM EDTHeron Therapeutics Q1 Earnings Call HighlightsHeron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter. Chief Executive Officer Craig Collard said the co
- Zacks · May 11, 9:30 AM EDTHeron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to SayThe headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Heron Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.